Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linvoseltamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Linvoseltamab (REGN-5458) is under development for the treatment of relapsed or refractory multiple myeloma. It acts by targeting cells expressing B-cell maturation antigen (BCMA) and CD3. The drug candidate is administered through intravenous route. It is a Bi-specific T-cell engager (BiTE) monoclonal antibody being developed based on VelociGene and VelocImmune platform technology. It was also under development for the treatment of hematologic and solid tumors.
For a complete picture of Linvoseltamab’s drug-specific PTSR and LoA scores, buy the report here.